Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Is Synageva BioPharma a Buy? Baker Bros. Thinks So

Is Synageva BioPharma a buy? Baker Bros. Advisors, a hedge fund managed by Julian and Felix Baker with a focus on biotechnology, increased its stake in Synageva BioPharma Corp (NASDAQ:GEVA) today. In a filing with the SEC, Baker Bros. disclosed ownership of 10.3 million shares of Synageva, which is higher than the previously held amount of some 9.2 million shares. The value of the current position, which represents 34% of the company, amounts to $641.1 million at the current price of company’s stock.


For the last quarter, Synageva reported revenues worth $3.4 million. The company also expanded its net loss, which amounted to $22.1 million, from $10.2 million reported for the same period of 2012, the company said in a statement. Also, last week the company announced that its previously revealed public offering of 2.75 million shares will be priced at $56.63 per share.

Aside from Baker Bros., we should mention some other hedge funds that owned shares of Synageva BioPharma in the latest round of 13F filings. As follows, at the end of last quarter, aside from Baker Bros, other hedge funds out of those we track held much smaller stakes. For example,Driehaus Capital, managed by Richard Driehaus held 148,400 shares. It is followed by SAC Capital subsidiary CR Intrinsic and Malcolm Fairbairn’s Ascend Capital, each owning 118,200 and 25,000 shares respectively.

Recommended Reading:

Glenn Greenberg, Brave Warrior Capital Reduce Higher One Stake

Cadian Now Owns 5.1% of Green Plains Renewable Energy Stock

Fosun International Thinks Perfect World Is Perfect

Disclosure: none

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.